Strides Pharma Receives EIR For Bengaluru Facility From U.S. FDA
An employee holds capsules for a photograph inside a coating unit at a pharmaceutical plant in Goa, India. Photographer: Dhiraj Singh/Bloomberg

Strides Pharma Receives EIR For Bengaluru Facility From U.S. FDA


Strides Pharma Science Ltd. on Monday said it has received Establishment Inspection Report for the inspection conducted by the U.S. FDA in January 2020 at company's flagship facility KRS Gardens, Bengaluru.

The inspection by the U.S. Food and Drug Administration was related to specific extended release applications made from the site. Receipt of EIR confirms the successful closure of the inspections, Strides Pharma Science said in a regulatory filing.

U.S. FDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.

Also read: Stocks In News: Hindustan Aeronautics, IndiGo, SpiceJet, Strides Pharma, Vedanta

"The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids," it added.

The facility is also capable of manufacturing complex formulations of extended release tablets which is one of the focus areas for the company.

Strides has a large extended release portfolio for the U.S. and other regulated markets with a capability to manufacture these products at multiple sites.

Also read: Dr. Reddy’s Labs To Seek Reinspection Of Key Cancer Drug Facility By USFDA

The company had recently also received EIR for Bengaluru facility from U.S. FDA for the inspection conducted in March 2020, it added.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.